IMPAX, Schering-Plough Settles Claritin-D 24-Hour Patent Suit

Law360, New York (October 27, 2003, 12:00 AM EST) -- Schering-Plough settled its patent lawsuit against generic drug maker IMPAX Laboratories, IMPAX said Monday.

As part of the agreement, IMPAX Laboratories entered into license agreement with Schering-Plough related to IMPAX's generic version of Claritin-D 24-Hour (Loratadine and Pseudoephedrine Sulfate, 10mg/240mg) Extended Release Tablets.

The agreement resolves all of the outstanding patent litigation between the parties on this product, IMPAX said.

"This case is currently at the summary motion phase and now, with this settlement, we can eliminate any additional expense or delays due to this lawsuit,"...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.